000503.SZ
国新健康
SZSE · Healthcare · I 信息技术 · CN
CNY 6.70
−2.47%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 350.5M | 350.4M | 356.9M | 330.1M | 311.1M |
| Cost of Revenue | 276.8M | 276.1M | 302.4M | 248.1M | 246.6M |
| Gross Profit | 73.7M | 74.3M | 54.4M | 82.0M | 64.5M |
| Operating Expenses | |||||
| R&D Expense | 2.7M | 2.8M | 339.3K | 967.9K | 9.6M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 129.8M | 131.0M | 118.1M | 128.4M | 130.8M |
| Selling & Marketing Expense | 82.1M | 80.9M | 72.3M | 62.0M | 32.9M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 227.4M | 226.0M | 195.2M | 197.7M | 176.3M |
| Cost and Expenses | 504.2M | 502.1M | 497.6M | 445.9M | 422.9M |
| Operating Income (EBIT) | (406.3M) | (402.6M) | (15.8M) | (82.7M) | (84.5M) |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | (407.6M) | (403.9M) | (11.7M) | (78.4M) | (83.2M) |
| Income Tax Expense | (550.9K) | 73.9K | (226.0K) | 1.9M | 1.1M |
| Bottom Line | |||||
| Net Income | (407.0M) | (404.0M) | (10.4M) | (79.8M) | (84.3M) |
| Earnings from Cont. Ops | (407.0M) | (404.0M) | (11.5M) | (80.3M) | (84.3M) |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | (407.0M) | (404.0M) | (10.4M) | (79.8M) | (84.3M) |
| Per Share | |||||
| Basic EPS | (CN¥0.42) | (CN¥0.41) | (CN¥0.01) | (CN¥0.09) | (CN¥0.09) |
| Diluted EPS | (CN¥0.42) | (CN¥0.41) | (CN¥0.01) | (CN¥0.09) | (CN¥0.09) |
| Revenue Per Share | CN¥0.36 | CN¥0.36 | CN¥0.36 | CN¥0.36 | CN¥0.34 |
| Shares | |||||
| Basic Shares Outstanding | 978.5M | 979.1M | 978.8M | 910.9M | 906.7M |
| Diluted Shares Outstanding | 978.5M | 979.1M | 978.8M | 910.9M | 906.7M |
| Profitability Metrics | |||||
| EBITDA | — | (373.6M) | 14.1M | (52.9M) | (54.9M) |
| D&A | — | 29.0M | 29.9M | 29.8M | 29.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026